SCH 900271 explained

SCH 900271 is a nicotinic acid derivative designed to treat dyslipidemia. It reduced plasma free fatty acids levels, but without significant flushing, a side effect common with niacin that limits its usefulness. SCH 900271 is currently in human trials.[1]

Notes and References

  1. Palani. Anandan. Discovery of SCH 900271, a Potent Nicotinic Acid Receptor Agonist for the Treatment of Dyslipidemia. ACS Medicinal Chemistry Letters. 3. 1. 63–8. November 2011. 10.1021/ml200243g. 24900372. 4025820.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "SCH 900271".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.